Accumulating evidence has delineated that LAG-3 is over-expressed on tumor-infiltrating CD8+ T cells in various tumor types, such as ovarian cancer, hepatocellular carcinoma, renal cell carcinomas and other solid tumors [32, 37, 38, 40, 41, 44, 56, 57]. This evidence concerns the gene CD8A and ovarian carcinoma.